Karl D. Lewis, MD, on Melanoma: Results From the BRIM8 Trial

2017 ESMO Congress
Tweet this page

Karl D. Lewis, MD, of the Anschutz Cancer Pavilion, discusses study findings on adjuvant vemurafenib in patients with completely resected BRAF V600–positive melanoma at high risk for recurrence (Abstract LBA7).

Advertisement

Advertisement



Advertisement